It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Ms Avital, who owns a health beverage company, rejected the whooping cough vaccine she was offered in week 28 of her pregnancy believing she "didn't need this crap".
She described herself as a very healthy, organic and fit woman who had no complications during her pregnancy and no deficiencies.
"[But] even me, the bulletproof lady who has never been to a doctor, travelled the world and felt healthy got whooping cough," she said.
The newborn is now in intensive care and entering her fourth week of the disease.
"It's just so hard to watch this tiny little thing ... go from red to blue, sometime they go a bit black, and for a moment you think they are dead in your hands, they flop."
Your child's protection against the disease increases with each shot, so her risk of getting it will be at its lowest after she receives the fifth shot of the series, between 4 and 6 years of age. Even then she has a small chance of coming down with whooping cough, because the vaccine isn't 100 percent effective.
The number of cases in the United States rose from about 1,000 in 1976 to almost 26,000 in 2005. (The number has declined somewhat since then.) Most of these infections were in babies younger than 6 months and children over age 7.
It's a shame that her wake up call was at the cost of her baby's health.
Monoclonal antibodies (mAbs) are now established as targeted therapies for malignancies, transplant rejection, autoimmune and infectious diseases, as well as a range of new indications. However, administration of mAbs carries the risk of immune reactions such as acute anaphylaxis, serum sickness and the generation of antibodies. In addition, there are numerous adverse effects of mAbs that are related to their specific targets, including infections and cancer, autoimmune disease, and organ-specific adverse events such as cardiotoxicity. In March 2006, a life-threatening cytokine release syndrome occurred during a first-in-human study with TGN1412 (a CD28-specific superagonist mAb), resulting in a range of recommendations to improve the safety of initial human clinical studies with mAbs. Here, we review some of the adverse effects encountered with mAb therapies, and discuss advances in preclinical testing and antibody technology aimed at minimizing the risk of these events.